Download PDF
Semin Plast Surg 2016; 30(01): 024-028
DOI: 10.1055/s-0036-1571302
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Botulinum Toxin in the Treatment of Pediatric Upper Limb Spasticity

Aloysia L. Schwabe
1   Department of Pediatric Physical Medicine and Rehabilitation, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
10 February 2016 (online)

    Permissions and Reprints

Abstract

Botulinum neurotoxin (BoNT) is one of the mainstays in the treatment of pediatric spasticity and dystonia. When considering initiation of BoNT treatment for spasticity, treatment goals and responses to prior conservative measures such as passive range of motion exercises, splinting, and other medication trials should be reviewed. As a general rule, children should be engaged in therapy services around the time of the injections and have a robust home program in place. When managing spasticity in children with BoNT injections, the practitioner should be well versed in functional anatomy with specialized training in injection techniques. Localization techniques in addition to anatomical landmarks are recommended for improved efficacy and include limited electromyography, electrical stimulation, and/or ultrasound guidance. A follow-up visit for the purpose of reassessment during the peak effect of the drug is advised. It is known that BoNT is effective at reducing spasticity and improving range of motion, but it remains to be determined to what degree this translates into improved function, activity, and participation.

Keywords

spasticity - cerebral palsy - botulinum toxin - neurotoxin
 

  • References

  • 1 Centers for Disease Control and Prevention. Cerebral palsy. Available at: http://www.cdc.gov/ncbdddd/cp/index.html . Accessed January 4, 2016
    PubMedGoogle Scholar
  • 2 Lieber RL, Fridén J. Spasticity causes a fundamental rearrangement of muscle-joint interaction. Muscle Nerve 2002; 25 (2) 265-270
    CrossrefPubMedGoogle Scholar
  • 3 Ting PT, Freiman A. The story of Clostridium botulinum: from food poisoning to Botox. Clin Med (Lond) 2004; 4 (3) 258-261
    CrossrefPubMedGoogle Scholar
  • 4 Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW ; Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111 (1) e89-e97
    CrossrefPubMedGoogle Scholar
  • 5 Jethwa A, Mink J, Macarthur C, Knights S, Fehlings T, Fehlings D. Development of the hypertonia assessment tool (HAT): a discriminative tool for hypertonia in children. Dev Med Child Neurol 2010; 52 (5) e83-e87
    PubMedGoogle Scholar
  • 6 Wallen M, O'Flaherty SJ, Waugh MC. Botulinum toxin type A and OT in the upper limbs of children with CP: a randomized controlled trial. Arch Phys Med Rehabil 2007; 88 (1) 1-10
    CrossrefPubMedGoogle Scholar
  • 7 Autti-Rämö I, Larsen A, Peltonen J, Taimo A, von Wendt L. Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia. Neuropediatrics 2000; 31 (1) 4-8
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Koman LA, Smith BP, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Pediatr Drugs 2003; 5 (1) 11-23
    CrossrefPubMedGoogle Scholar
  • 9 Naidu K, Smith K, Sheedy M, Adair B, Yu X, Graham HK. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Dev Med Child Neurol 2010; 52 (2) 139-144
    CrossrefPubMedGoogle Scholar
  • 10 Smania N, Colosimo C, Bentivoglio AR, Sandrini G, Picelli A. Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey. Funct Neurol 2013; 28 (4) 253-258
    PubMedGoogle Scholar
  • 11 Chin TY, Nattrass GR, Selber P, Graham HK. Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop 2005; 25 (3) 286-291
    CrossrefPubMedGoogle Scholar
  • 12 Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology 2002; 58 (5) 805-807
    CrossrefPubMedGoogle Scholar
  • 13 Chiou-Tan F, Cianca J, John J, Furr-Stimming E, Pandit S, Taber KH. Procedure oriented torsional anatomy of the forearm for spasticity injection. J Comput Assist Tomogr 2015; 39 (5) 820-823
    CrossrefPubMedGoogle Scholar
  • 14 Naumann M, Carruthers A, Carruthers J , et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010; 25 (13) 2211-2218
    CrossrefPubMedGoogle Scholar
  • 15 Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit?. Curr Opin Neurol 2001; 14 (6) 771-776
    CrossrefPubMedGoogle Scholar
  • 16 Goldstein EM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 2006; 21 (3) 189-192
    CrossrefPubMedGoogle Scholar
  • 17 Chhina H, Howren A, Simmonds A, Alvarez CM. Onabotulinumtoxin A injections: a safety review of children with clubfoot under 2 years of age at BC Children's Hospital. Eur J Paediatr Neurol 2014; 18 (2) 171-175
    CrossrefPubMedGoogle Scholar
  • 18 Pascual-Pascual SI, Pascual-Castroviejo I. Safety of botulinum toxin type A in children younger than 2 years. Eur J Paediatr Neurol 2009; 13 (6) 511-515
    CrossrefPubMedGoogle Scholar